Document is current

Article History

Received: 13 November 2025

Accepted: 30 March 2026

First Online: 21 April 2026

Declarations

:

: Megan E. B. Clowse: Grant/research support from: UCB, GSK. Consultant for: UCB, GSK; Radboud J. E. M. Dolhain: Unrestricted research grants from: Dutch Arthritis Association, ZonMw, UCB and Galapagos. Speaking fees from: UCB, Roche, AbbVie, Genzyme, Novartis, AstraZeneca and Eli Lilly; Stephanie Finzel: Grant/research support from: Novartis. Consultant for: Novartis, NovoNordisk. Speaker’s honoraria: AbbVie, Chugai, Galapagos, GSK, Novartis, UCB; Frauke Förger: Grant/research support from: UCB. Speaker’s bureau: Mepha, Roche, UCB, MSD; Cornelia Glaser: Speaker’s honoraria: Galapagos, GSK, Pfizer, UCB; Andrea Pluma: Speaker’s honoraria: UCB. Support for attending educational events: Fresenius, UCB. Participation Advisory Board: Galapagos; Laura Shaughnessy, Jagdev Sidhu, Jemma Greenin, Kathy Rice, Joao N. Duarte, Marie Teil: Employee and shareholder of UCB. Gauri Utturkar: Former Employee of UCB; employee of GSK.

: The CHERISH study protocol, amendments, and patient informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB) (Supplementary Table 4). CHERISH was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Full details of the ethics committee involved are available upon request. All patients provided written informed consent to participate in the study, with the addition of obtaining parental consent where relevant.